Paper7296754
Experimental in vivo cross-resistance of vinca alkaloid drugs.
Maral R and 3 others. Cancer Chemother Pharmacol, 1981. Cited by 29 papers, by iCite.
Cite this record
ConductScience Library. Experimental in vivo cross-resistance of vinca alkaloid drugs. Papers, record 7296754. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7296754
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Vinca Alkaloids | Major topic |
| Animals | |
| Drug Resistance | |
| Leukemia P388 | |
| Male | |
| Mice | |
| Vinblastine | |
| Vincristine | |
| Vindesine | |
| Vinorelbine |
Source PubMed
References12
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 287569 | Phase-II trial with vindesine for regression induction in patients with leukemias and hematosarcomas. | Cancer Chemother Pharmacol | 1979 | https://conductscience.org/library/papers/287569 | PubMed |
| 2 | 445418 | Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia. | Cancer Res | 1979 | https://conductscience.org/library/papers/445418 | PubMed |
| 3 | 455579 | Vindesine. A short review of preclinical and first clinical data. | Cancer Chemother Pharmacol | 1979 | https://conductscience.org/library/papers/455579 | PubMed |
| 4 | 329987 | Phase I anti-cancer agents: vindesine (desacetyl vinblastine amide sulfate). | Cancer Treat Rev | 1977 | https://conductscience.org/library/papers/329987 | PubMed |
| 5 | 922743 | Decreased retention of actinomycin D as the basis for cross-resistance in anthracycline-resistant sublines of P388 leukemia. | Cancer Res | 1977 | https://conductscience.org/library/papers/922743 | PubMed |
| 6 | 274996 | Phase II clinical trial with vindesine for remission induction in acute leukemia, blastic crisis of chronic myeloid leukemia, lymphosarcoma, and hodgkin's disease: absence of cross-resistance with vincristine. | Cancer Treat Rep | 1978 | https://conductscience.org/library/papers/274996 | PubMed |
| 7 | 709555 | In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia. | Cancer Treat Rep | 1978 | https://conductscience.org/library/papers/709555 | PubMed |
| 8 | 24294903 | A new class of antitumor compounds: 5'-nor and 5',6'-seco derivatives of vinblastine-type alkaloids. | J Org Chem | 1979 | https://conductscience.org/library/papers/24294903 | PubMed |
| 9 | 7001942 | A study of the cross-resistance of vincristine and vindesine in reinduction therapy for acute lymphocytic leukemia in relapse. A report for Children's Cancer Study Group. | Am J Pediatr Hematol Oncol | 1980 | https://conductscience.org/library/papers/7001942 | PubMed |
| 10 | 6159973 | Comparative effects of vincristine and vindesine on cell cycle kinetics in vitro. | Cancer Treat Rev | 1980 | https://conductscience.org/library/papers/6159973 | PubMed |
| 11 | 412968 | Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate. | J Med Chem | 1978 | https://conductscience.org/library/papers/412968 | PubMed |
| 12 | 7387723 | Cross resistance between actinomycin-D, adriamycin and vincristine in a murine solid tumour in vivo. | Biochem Pharmacol | 1980 | https://conductscience.org/library/papers/7387723 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 29 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 20809205 | A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor. | Invest New Drugs | 2012 | https://conductscience.org/library/papers/20809205 | PubMed |
| 7803948 | Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy. | Drugs Aging | 1994 | https://conductscience.org/library/papers/7803948 | PubMed |
| 7105380 | Establishment of Vincristine-resistant and vindesine-resistant lines of murine lymphoblasts in vitro and characterisation of their patterns of cross-resistance and drug sensitivities. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7105380 | PubMed |
| 3698163 | Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats. | Cancer Chemother Pharmacol | 1986 | https://conductscience.org/library/papers/3698163 | PubMed |
| 1742851 | Pharmacokinetics of navelbine after oral administration in cancer patients. | Cancer Chemother Pharmacol | 1991 | https://conductscience.org/library/papers/1742851 | PubMed |
| 1283846 | Preclinical and clinical pharmacology of vinca alkaloids. | Drugs | 1992 | https://conductscience.org/library/papers/1283846 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/7296754
GET https://conductscience.org/api/papers/v1/7296754/authors